New therapies for diabesity

Research output: Contribution to journalArticlepeer-review


Many patients with type 2 diabetes are obese (diabesity), and the two conditions together impose a particularly complex therapeutic challenge. Several differently acting agents are often required at the same time, encouraging development of more single-tablet combinations. Longer-acting (once daily and once weekly) injected agonists of glucagon-like peptide-1 are due to provide additional options to stimulate insulin secretion with weight loss and minimal risk of hypoglycemia. Further, dipeptidyl peptidase-4 inhibitors ("weight-neutral" insulinotropic agents) are also expected. Sodium-glucose cotransporter 2 inhibitors offer a new option to reduce hyperglycemia and facilitate weight loss by increasing the elimination of glucose in the urine. Selective peroxisome proliferator-activated receptor modulators are being studied to produce compounds with desired effects. Many other agents with antidiabetic and antiobesity activity are progressing in clinical development.
Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalCurrent Diabetes Reports
Issue number5
Publication statusPublished - Oct 2009


  • anti-obesity agents
  • type 2 diabetes mellitus
  • dipeptidyl-peptidase IV inhibitors
  • glucagon-like peptide 1
  • humans
  • hypoglycemic agents
  • obesity
  • sodium-glucose transporter 2


Dive into the research topics of 'New therapies for diabesity'. Together they form a unique fingerprint.

Cite this